Chemexpress, founded in 2006, is a leading provider of small molecule and new modalities CDMO services for the pharmaceutical and biotech industries. With a comprehensive CRO & CDMO platform, they specialize in research and development, manufacturing, and supply of regulatory starting materials, intermediates, APIs, and drug products. As a one-stop service platform, Chemexpress supports clients' projects from early drug discovery to commercialization.

Over the past 16 years, Chemexpress has established a state-of-the-art QC/QA system that aligns with ICH guidelines for pharmaceutical manufacturing. With a commitment to high-quality products and CMC services, they cater to the entire lifecycle of drug development. Their services include discovery, synthetic chemistry, medicinal chemistry, process development, formulation development, manufacturing (APIs, intermediates, and drug products), and regulatory CMC support.

Chemexpress also specializes in ADC, high potency API, oligonucleotide process development and manufacturing, as well as analytical development and quality control. Utilizing cutting-edge technologies such as high-throughput experimentation, flow chemistry, biocatalysis, and more, Chemexpress stays at the forefront of innovation in the field. Through their dedication and expertise, they aim to bring valuable therapeutics to patients at a faster rate and lower cost.

With a team of experienced leadership, including CTO/Sr. VP Yonggang Chen, Co-Founder CSO Shuoliang Li, VP/GM of Manufacturing Division Shaobo Yang, and CQO/Sr. VP GM of Ma'anshan Site Jack Sheng, Chemexpress ensures the highest standards of quality and service.

Located in Shanghai, China, Chemexpress operates globally with over 7000 partners. They can be reached at their HQ address or through their contact details provided on their website